Pharmaceuticals, Biotechnology and Life Sciences
– Multiple value-driving milestones expected throughout 2021
– Trappsol® Cyclo™ Niemann Pick Disease Type C (NPC) clinical program on track to imminently report topline results from Phase 1/2 study
– Company expects to commence enrollment in pivotal…
Update on Phase 3 REVERSE-IT trial – enrollment ahead of schedule
Provides overview of bentracimab development program during virtual Investor & Analyst Day, March 15, 2021, 12 – 2 pm ET
Announced commercial supply agreement with BioVectra to s…
Takeda to have access to Genevant’s innovative LNP technology to develop nucleic acid therapeutics directed to specified targets in historically inaccessible hepatic stellate cells to treat liver fibrosis
Genevant initially eligible for up to $600 mi…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced availability of data presen…
— Single-Dose Antibiotic with One-Hour Infusion, Additional Compatibilities in Normal Saline and D5W, and Lower Infusion Volume–
— Launch Expected in Summer 2021–
MORRISTOWN, N.J.–(BUSINESS WIRE)–Melinta Therapeutics, LLC (Melinta), a commercia…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced its oral and poster present…
BELGRADE, Mont.–(BUSINESS WIRE)–Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announced today that the Company will change its business strategy to focus on the fast growing psychedelics and cannabis market…
− Takeda will make manufacturing capacity available at IDT’s facilities in Germany
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), …
Total of $195 million raised to date to support expansion and clinical advancement of Graphite Bio pipeline of targeted gene integration therapies with curative potential
The financing, led by RA Capital Management and Rock Springs Capital, includ…
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a busines…